Aktuellt
SENASTE
Redeye is surprised by the recently announced withdrawal of AroCell’s FDA application, which effectively cut its share price in half. The decision based on the FDA’s conclusion that there is no predicate device to base its application upon puts AroCell several steps back for its breast cancer indication.
LÄS MER
